production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system," issued a press release on October 17, 2025, ...

Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), ...

The collaboration between the University and CyanoCapture will focus on developing innovative methods for producing targeted delivery systems using engineered carboxysomes, combining advanced ...

The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based ...

Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw ...

“Dyadic is advancing its transition to ... These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ ...

For decades, synthetic biologists have been developing gene circuits that can be transferred into cells for applications such as reprogramming a stem cell into a neuron or generating a protein that ...

Researchers at UMC Utrecht have discovered that converting monoclonal antibodies from the IgG to the IgM isotype can significantly broaden their ability to recognize and bind multiple human-relevant ...

Nobel Prize winners, from left: Mary Brunkow, senior program manager at the Institute for Systems Biology, Fred Ramsdell, co-founder and chair of Sonoma Biotherapeutic’s scientific advisory board; and ...

Objectives Patients with primary Sjögren’s disease (SjD) have an increased risk of B cell lymphoma. The aim of this study was ...

Proteins sourced from microorganisms are attracting attention for their potential in biomanufacturing a variety of products, ...